To evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS). ⋯ A reduced dose of 36-Gy EBRT after delayed GTR may maximize local control while minimizing long-term sequelae for very young children with RMS, but unresectable tumors (e.g., parameningeal) require higher doses. Normal-tissue-sparing techniques such as intensity-modulated radiation therapy and IOHDR are encouraged. Local control may be maximized when EBRT begins
PurposeTo evaluate local control and toxicity for very young children treated with multimodality therapy for rhabdomyosarcoma (RMS).Methods And MaterialsFrom 1990 to 2004, 20 patientsor=1 year after diagnosis (15) in terms of mild, moderate, or severe deficits.ResultsMedian follow-up was 33 months for survivors and 23 months for all patients. Two-year actuarial local control, event-free survival, disease-specific survival, and overall survival were 84%, 52%, 74%, and 62%, respectively. All patients who began EBRTConclusionsA reduced dose of 36-Gy EBRT after delayed GTR may maximize local control while minimizing long-term sequelae for very young children with RMS, but unresectable tumors (e.g., parameningeal) require higher doses. Normal-tissue-sparing techniques such as intensity-modulated radiation therapy and IOHDR are encouraged. Local control may be maximized when EBRT begins